Health Care

  • Implant This

    Roger Montgomery
    February 25, 2015

    As you know, one of the positive arguments for Montgomery funds investing in Medibank Private, is the ability of the company to harness rapidly-advancing technologies to improve patient outcomes and lower private health insurance claims.

    In the US the question being asked is; Why give your doctors permission to incorporate data from fitness trackers and health apps into electronic patient records? continue…

    by Roger Montgomery Posted in Health Care, Insightful Insights, Technology & Telecommunications.

  • Please Sign Here

    Ben MacNevin
    February 25, 2015

    NIB Holdings (ASX: NHF) has reported hospital claims inflation of 17 per cent for the first half of the 2015 financial year, which we believe demonstrates the inferior position of the smaller funds in the health care chain. continue…

    by Ben MacNevin Posted in Health Care, Insightful Insights, Insurance.

  • Sirtex – a stronger result than we expected

    Russell Muldoon
    February 21, 2015

    We take a look at Sirtex Medical Limited’s half-year result to 31 December 2014. According to Portfolio Manager, Russell Muldoon, the result is much stronger across the board, than previously modeled, particularly in dosage sales (volumes), price increases and average selling prices.

    Sirtex’s half-year result is further evidence of our current belief in the business’s underlying strength and management’s strategy.

    EXCLUSIVE CONTENT

    subscribe for free
    or sign in to access the article
    Subscribe Sign In

    continue…

    by Russell Muldoon Posted in Companies, Health Care.

  • WHITEPAPERS

    CSL – we like what we see

    Russell Muldoon
    February 17, 2015

    We take a look at CSL Limited’s half-year result to 31 December 2014. CSL is a global specialty biotechnology company that researches, develops, manufactures and markets products to treat and prevent serious human medical conditions. While the market is focusing on Immunoglobulin, and the potential supply growth from competitors, the story is much bigger than this and we should avoid getting too caught-up in the short-term.

    EXCLUSIVE CONTENT

    subscribe for free
    or sign in to access the article
    Subscribe Sign In

    CSL is a major holding in both The Montgomery Fund and The Montgomery Private Fund.

    Russell Muldoon is the Portfolio Manager of The Montgomery [Private] Fund. To invest with Montgomery, find out more.

    by Russell Muldoon Posted in Health Care, Whitepapers.

  • Sirtex Medical vs BTG?

    Russell Muldoon
    December 18, 2014

    We have watched the share price fall in Sirtex Medical over the past week with some interest, and whilst we don’t take our cues from price action alone, we did a fair amount on enquiry as to what had spooked investors over such a short space of time. continue…

    by Russell Muldoon Posted in Health Care, Insightful Insights, Investing Education.

  • WHITEPAPER

    HIGHER RETURNS AND LOWER RISK? YES, IT’S POSSIBLE WITH PRIVATE CREDIT

    Discover how private credit can deliver higher returns with lower risk in our latest whitepaper. Learn how the Aura Core Income Fund’s AA equivalent rated portfolio has consistently outperformed while maintaining transparency and robust risk management. Unlock the insights to achieve superior risk-adjusted returns today. 

    READ HERE

  • Who holds the keys to health?

    Ben MacNevin
    December 8, 2014

    Having recently returned from a comprehensive tour of healthcare companies with our friends at UBS, we gleaned a highly important understanding of where the bargaining power lies in the industry. From this tour, it was abundantly clear whose interests matter most.

    In essence, every element of the health care sector is dependent upon the doctors – this is across hospitals, health funds, pathology, service providers and medical device distributors. continue…

    by Ben MacNevin Posted in Health Care, Insightful Insights, Investing Education.

  • Looking at Ansell’s Long Term Incentive Plan

    Ben MacNevin
    November 18, 2014

    Upon examining Ansell’s (ASX:ANN) Long Term Incentive Plan for management, we have noticed some interesting developments in the company’s capital position. continue…

    by Ben MacNevin Posted in Consumer discretionary, Health Care, Insightful Insights, Investing Education.

  • Healthscope vs Ramsay Health Care

    Ben MacNevin
    November 12, 2014

    Healthscope (ASX: HSO) and Ramsay Health Care (ASX: RHC) hotly contested the Northern Beaches hospital tender at Sydney’s Frenchs Forest, with Healthscope emerging victorious. Should Ramsay shareholders be concerned? continue…

    by Ben MacNevin Posted in Health Care, Insightful Insights, Montgomery News and Updates.

  • Sirtex: A bright future

    Russell Muldoon
    October 29, 2014

    Yesterday, Sirtex (ASX: SRX) held their AGM, where CEO Gilman Wong provided an excellent address containing a lot of quality information for investors. We thought it was worth sharing some of his insights here.

    Among other things, he provided an update on how the business is travelling year-to-date (YTD). Given they are no longer providing quarterly updates, this was a nice-to-have – especially when others speak of key trials, management expectations and future business prospects.

    Also, for the first time Gilman presented some information surrounding completely new treatments SRX has been developing in conjunction with universities (some of which we, even after following the business closely for many years) were unaware of.

    From the 26-page presentation, these are the comments and slides that caught our attention.

    • The 2014 financial year was a highly productive period for Sirtex, as we recorded our 40th consecutive quarter of growth in sales of SIR-Spheres microspheres. We are proud of our growth record and I am pleased to say this trend is continuing and at close of business yesterday YTD dose sales were up 28.7 per cent on the same period last year. Our goal now is to launch our business higher into new levels of growth.
    • More and more medical professionals around the world are beginning to realise the enormous potential of our targeted liver cancer therapy to treat a wide range of patients and are hence making the decision to use SIR-Spheres microspheres.
    • It is worth noting the news announced a few weeks ago that ESMO, the European Society for Medical Oncology, has identified SIR-Spheres Y90 resin microspheres as an appropriate treatment for patients with colorectal liver metastases that have failed to respond to chemotherapy. We believe the new ESMO clinical guidelines will have a positive effect on improving patient access to SIR-Spheres microspheres across Europe.
    • Sirtex’s business in the Asia Pacific is still very much in its infancy but has enormous potential and we continue to create a foothold in new markets.
    • Sirtex believes the SIRFLOX result should be positive. This is an evidence based view, founded on the results of six previously completed, albeit smaller clinical studies and the results of two large scale retrospective analyses which were all positive. Indeed, to date there has not been a failed study of SIR-Spheres microspheres.
    • A positive result however, should see an acceleration in dose sales growth rates, and potentially a step change in growth in terms of multiples of our current dose sales. Growth is not expected to be instantaneous, but rather a ramp up over ensuing years.
    • Several years ago we initiated a clinical study strategy involving five major studies. Unlike many companies that rely on one study, Sirtex has covered many bases and the results of each of our studies can provide significant impact. As our large global studies in metastatic colorectal cancer and hepatocellular carcinoma progress towards completion, we are broadening our focus beyond the liver towards the potential use of SIR-Spheres microspheres to treat cancers in other organs. Leading this program is our RESIRT study investigating the use of SIR-Spheres microspheres in kidney cancer patients. Other studies are planned and we will be providing details once these are confirmed.
    • During the year, two new hot cells have been installed in our expanded US facility in Wilmington and the fit-out of our new German manufacturing plant in Frankfurt is on time and on budget. We are well prepared to meet the anticipated sales growth in our current market and new markets.
    • Looking to the future, we are working on some highly promising technologies. A good example is the Carbon Cage Nanotechnology that we are developing with the Australian National University. Carbon Cage Nanoparticles can carry a high internal payload of radioactive material which is encapsulated in an outer carbon shell. This carbon shell is chemically inert and possesses ideal properties for the attachment of coatings for a variety of purposes, for example to target specific cancers or to impart stealth-like properties, thereby enhancing their ability to evade detection by the immune system. Carbon Cage Technology could be used in a range of new diagnostic or therapeutic agents with unique characteristics compared to the current state of the art. Our collaboration with the National Cancer Centre of Singapore is to investigate the application of the Carbon Cage Nanotechnology to prevent spread of metastasis after surgery to treat ovarian cancer.
    • All of our research programs have the potential to equal or exceed the market potential for SIR-Spheres microspheres.

     

    And perhaps the most important of all of these is the following:

    • Together with our customers and collaborators in the medical community, Sirtex shares a common vision where cancer is a treatable chronic condition that patients can successfully live with or be cured from. It is an ambitious goal but one for which there are many precedents. Diseases like HIV, diabetes and heart disease were all considered terminal conditions a few decades ago. Advances in medicine have seen these conditions become chronic conditions people can successfully live with. With liver cancer, we are witnessing a growing body of independent medical evidence that indicates an increasing number of patients are now able to live with their disease. These good outcomes are due to a number of medical innovations which includes SIR-Spheres microspheres.
    • To date we have supplied more than 45,000 doses of SIR-Spheres microspheres globally. One of the people to have been treated with SIR-Spheres microspheres is a woman in Melbourne, Elizabeth Deylen. In 2012, Elizabeth was told she had stage four bowel cancer with metastases to her liver and that she had only a few months to live. She was treated with SIR-Spheres microspheres prescribed by medical oncologist Professor Peter Gibbs and his team at the Royal Melbourne Hospital. Two years on and Elizabeth no longer has signs of cancer in her liver and she recently celebrated her 50th birthday in Bali with her family.

    What an exciting, Australian-made medical device.

    2910_srx

    by Russell Muldoon Posted in Companies, Health Care, Insightful Insights.

  • A bargain buy

    Roger Montgomery
    October 29, 2014

    The best investments are those you can pick up for a bargain, but not because the shares get slammed amid a short-term setback. The very best are those that trade at a discount to intrinsic value for a long time, because nobody notices or cares. CSL Limited (ASX: CSL) is one of those unexciting businesses that even owners of so-called ‘blue-chip’ portfolios only hold occasionally.
    continue…

    by Roger Montgomery Posted in Health Care, Insightful Insights, Investing Education.